Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | HPGDS | O60760 | 5/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757526 | 0.82 | KDM1A (0.36) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL445603 | 0.78 | KDM1A (0.39) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL20160685 | 0.78 | KDM1A (0.39) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL459481 | 0.76 | GNAI3 (0.39) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL445604 | 0.76 | KDM1A (0.38) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL1978527 | 0.76 | KDM1A (0.38) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL20635752 | 0.76 | KDM1A (0.38) | KDM1AHPGDSJAK1GPR119JAK2 | |
| SCHEMBL834995 | 0.76 | ACHE (0.43) | KDM1AHPGDSGPR119 | |
| SCHEMBL25235628 | 0.76 | KDM1A (0.34) | KDM1A | |
| SCHEMBL22727531 | 0.74 | KDM1A (0.37) | KDM1AHPGDSJAK1GPR119JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-2086551-A2 | THROMBOPOIETIN MIMETICS | Stategics, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | KDM1A 2809/4885HPGDS 182/4885JAK1 168/4885 |
| US-20100323965-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | KDM1A 2809/4885HPGDS 182/4885JAK1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.